Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 20 years outpatient (regardless of sex)~* Patients diagnosed as non-valvular atrial fibrillation (NVAF)~* One or more following risks of stroke.~Exclusion Criteria:~* Recent cerebral infarction (includes TIA) within 4 weeks of week 0.~* Subjects who have or are suspected to have a serious/hereditary bleeding tendency, such as disseminated intravascular coagulation syndrome (DIC), congenital platelet dysfunction and von Willebrand disease (those suspected from the family history are included).~* Subjects who have or are suspected to have a serious/hereditary thrombogenic tendency (those suspected from the family history are included) or those who require continuation of the Warfarin therapy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban 5mg BID (Type: EXPERIMENTAL): None
- Apixaban 2.5mg BID (Type: EXPERIMENTAL): None
- Warfarin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).